JPMorgan initiated coverage of Absci (ABSI) with an Overweight rating and no price target Absci is an artificial intelligence-driven platform company developing novel therapeutics, the analyst tells investors in a research note. The firm says the company’s expertise in the computational space has the “attractive potential” in changing how new therapeutics are found. Absci is will reach a major inflection point with the first interim clinical data cut later this year, contends JPMorgan.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABSI:
- Absci announces collaboration with Oracle Cloud Infrastructure, AMD
- Absci Corp. Earnings Call: Strategic Gains Amid Challenges
- Promising Potential of AbSci’s ABS-201 Therapy for Androgenetic Alopecia: A Buy Recommendation
- Promising Developments and Strong Financial Position Bolster AbSci’s Growth Prospects
- AbSci’s Positive Outlook: Strong Financial Position and Promising ABS-101 Developments Support Buy Rating